Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) submitted its Monthly Return on Movements in Securities for the period ending 31 March 2026, indicating no changes to its share capital structure.

Boan Biotech’s registered and issued share capital closed the month at 0.62 billion ordinary H-shares, each with a par value of RMB 1, translating to RMB 622.33 million in registered share capital. Treasury shares remained at zero, and no share issuances, cancellations, repurchases, options, warrants, convertibles, or other equity-linked instruments were reported during the month.

The company confirmed compliance with the Hong Kong Stock Exchange’s public-float rules. Pursuant to a previously granted waiver, Boan Biotech must maintain at least an 18.14 % public float—equivalent to the level at its December 2022 listing—and this threshold was met as of 31 March 2026.

Director Jiang Hua certified that all regulatory and listing-rule requirements related to any securities activities during the month were fully observed.